C-ILI6EXO Biologics
exosomes, extracellular vesicles, MSC-derived EVs
deliverydeliveringextracellular vesicle
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ILI6
C-ILI6C-ILI6exosomes, extracellular vesicles, MSC-derived EVs
0-100 chain-logic scale · 15 dimensions · scored on public evidence
EXO Biologics exosomes, extracellular vesicles, MSC-derived EVs
EXO Biologics is a Belgian biotech company developing biopharmaceuticals using Extracellular Vesicles and exosomes. Its strategy focuses on rare inflammatory diseases, drug loading and delivery, and a GMP manufacturing platform for research and clinical use. The company states that its lead indication is bronchopulmonary dysplasia in preterm babies.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
EXO Biologics — Translational · Bottom quartile. Derived deterministically from 8 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic